What is Teriflunomide?
Category: Prescription Drugs
Most popular types: Aubagio
Teriflunomide is thought to prevent the interaction of cells in the immune system involved in damage to the myelin sheath. It is used to treat relapsing-remitting Multiple Sclerosis.
| Purpose | Patients | Evaluations | Perceived Effectiveness |
|---|---|---|---|
| Multiple sclerosis | 2210 | 296 | |
| Participate in clinical trial | 12 | 10 | |
| Balance problems | 1 | 0 | |
| Infantile myofibromatosis | 1 | 0 | |
| Numbness | 1 | 0 |
- Major
- Moderate
- Slight
- None
- Can't tell
Side effects
Side effects as an overall problem
| Severity | Evaluations | Percentage |
|---|---|---|
| Severe | 45 | |
| Moderate | 49 | |
| Mild | 76 | |
| None | 138 |
Commonly reported side effects and conditions associated with Teriflunomide
| Side effect | Patients | Percentage |
|---|---|---|
| Hair loss | 38 | |
| Diarrhea | 22 | |
| Nausea | 14 | |
| Hair thinning | 12 | |
| Headaches | 9 | |
| Elevated blood pressure | 6 |
Why patients stopped taking Teriflunomide
Multiple reasons could be selected
| Reason | Patients | Percentage |
|---|---|---|
| Side effects too severe | 51 | |
| Did not seem to work | 41 | |
| Doctor's advice | 29 | |
| Other | 14 | |
| Expense | 4 | |
| Change in health plan coverage | 3 | |
| Course of treatment ended | 3 | |
| Personal research | 3 |
Duration
Stopped taking Teriflunomide
| Duration | Patients | Percentage |
|---|---|---|
| Less than 1 month | 11 | |
| 1 - 6 months | 31 | |
| 6 months - 1 year | 22 | |
| 1 - 2 years | 21 | |
| 2 - 5 years | 27 | |
| 5 - 10 years | 4 | |
| 10 years or more | 1 |
What people switch to and from
Patients started taking Teriflunomide after stopping:
| Treatment | Patients | Percentage |
|---|---|---|
| Dimethyl fumarate (Tecfidera) | 66 | |
| Glatiramer acetate (Copaxone) | 58 | |
| Interferon beta-1a IM Injection (Avonex) | 31 | |
| Interferon beta-1a SubQ injection (Rebif) | 21 | |
| Natalizumab (Tysabri) | 20 |
Patients stopped taking Teriflunomide and switched to:
| Treatment | Patients | Percentage |
|---|---|---|
| Ocrelizumab (Ocrevus) | 23 | |
| Glatiramer acetate (Copaxone) | 17 | |
| Dimethyl fumarate (Tecfidera) | 15 | |
| Natalizumab (Tysabri) | 15 | |
| Alemtuzumab (Lemtrada) | 6 |
Last updated: